new-recommended-broker-banner new-recommended-broker-banner
Practice Stock Trading Your Capital Is At Risk

NanoVibronix Stock Price Soars 21% After Positive Double-Blind Study for ‘Tennis Elbow’

Updated: 11 Oct 2021

On a good day for NanoVibronix investors, the stock price soared to highs of over 20% gains as Monday’s market opened for trading. The spike hit in early premarket, attracting further attention as the trading commenced.

The spike is due to the latest news announcement from state-of-the-art medical device company NanoVibronix; specialists in their own, patented, acoustic wave technology. In the latest set of public data, claims regarding their new product ‘PainShield’ and its potential to treat, or lateral epicondylitis, known as ‘tennis elbow’.

Positive results from the randomized, double-blind study had a direct effect on NAOV price- with 91% of participants stating either a complete or partial resolution of symptoms – sending the stock soaring as soon as the information reached the eager ears of investors. The PainSheld is designed for use without opioid-based prescription medication.


Dr. David Lemak, MD, Lead Investigator of the study, makes particular reference to the focus on restricting the prescription of opioid use:

“Patient outcomes were markedly improved with the use of PainShield and importantly, no patients returned with signs or symptoms of an exacerbation. Most encouraging are the results we were able to achieve for our patients without the use of prescription opioid medications, which can often lead to prolonged use and addiction.”

The breakthrough treatment provoked a welcoming reaction from the market today, and while the stock price has lost some of its premarket power, the current price of $1.92 relays a current increase of 12%.

Should You Invest in NanoVibronix Shares?

One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .